Trials / Completed
CompletedNCT01510626
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 4 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies. The investigators hypothesize that the application of this protocol will allow patients with severe and single or multiple food allergies to be safely and rapidly desensitized.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Food proteins | Food proteins |
| DRUG | Omalizumab | Drug |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2014-04-01
- Completion
- 2015-12-01
- First posted
- 2012-01-16
- Last updated
- 2015-12-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01510626. Inclusion in this directory is not an endorsement.